胰腺癌qBiomarke体细胞突变PCR芯片 Pancrea

“英拜为您实验加速”
技术服务网址：http://www.yingbio.com/
服务热线：400-696-6643、 18019265738
邮箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

Pancreatic Cancer qBiomarker Mutation PCR Array

胰腺癌qBiomarke体细胞突变PCR芯片

Product	Species	Technology	Cat. No.
Pancreatic Cancer qBiomarker Mutation PCR Array	Human	Somatic Mutation	SMH-035A

The Human Pancreatic Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the somatic mutations in human pancreatic cancer samples in the following key genes: APC, BRAF, CDKN2A, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and P53. These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Pancreatic Cancer qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of pancreatic cancer and has the potential for discovery and development of effective biomarkers for this cancer type and other cancer types in which these mutations were identified. This array includes 38 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human pancreatic cancer. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent the most frequently recurring somatic mutations compiled from over 3800 pancreatic cancer samples. Each 96-well array allows profiling mutation status of 2 samples, while each 384-well format array allows mutation profiling of 8 samples. The simplicity of the product format and operating procedure enables routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments
胰腺癌qBiomarke体细胞突变PCR芯片是一个翻译研究工具,用于快速,准确,全面剖析胰腺癌样本中体细胞突变的关键基因：APC, BRAF, CDKN2A, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, 和 P53. 这些突变保证广泛的研究,以提高致癌作用的理解和鉴定潜在的药物靶点。已有许多研究通过单个和多个体细胞突变状态信息鉴定关键信号转导中断。例如,EGFR和KRAS基因的突变状态可以预测某些药物针对这些分子的生理反应。胰腺癌qBiomarker体细胞突变PCR芯片以其全面的内容覆盖范围，用于研究卵巢癌的环境突变且有潜力用于发现靶向药物的生物标记和验证这些癌症和其他这些突变已确定的癌症。这个芯片包含38个DNA突变序列用于检测最频繁的，功能性验证，在人类胰腺癌上有生物学意义的显著突变。这些突变的选择根据全面的体细胞突变数据库和文献，来自3800多个卵巢癌样本发生最频繁重复编译的体细胞突变。简单的产品模式和操作程序让任何一个具备实时定量PCR仪的实验室都可进行常规的体细胞突变分析。
APC: 1 Assay
The most commonly detected APC inactivation mutations are mainly composed of truncation mutations (due to nonsense mutations and frameshift mutations) and point mutations between codons 1250 and 1578.
BRAF: 1 Assay
The most important BRAF mutation in pancreatic cancer leads to increased kinase activity, the p. V600E mutation.
CDKN2A: 3 Assays
The top CDKN2A loss-of-function mutations occur in the consensus ankyrin domain, which leads to inability to form stable complexes with its targets.
CTNNB1: 9 Assays
The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
KRAS: 10 Assays
The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
NRAS: 2 Assays
The most important NRAS mutations in pancreatic cancer occur at codon 61.
PIK3CA: 3 Assays
The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
SMAD4: 1 Assay
SMAD4 encodes a member of the Smad family of signal transduction proteins. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome.
TP53: 8 Assays
The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure.

工作原理：

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS®